International Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy.

This open-label, single arm study will investigate the safety, tolerability and efficacy of
tocilizumab monotherapy, or combination therapy with non-biologic disease modifying
antirheumatic drugs (DMARDs), in patients with severe active RA. Patients will receive
tocilizumab 8mg/kg iv as a 60 minute infusion every 4 weeks for a total of 6 infusions. The
anticipated time on study treatment is 3-12 months, and the target sample size is >500
individuals.